586 related articles for article (PubMed ID: 23992517)
1. A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE.
Hess CN; Al-Khatib SM; Granger CB; Lopes R
Expert Rev Cardiovasc Ther; 2013 Sep; 11(9):1105-14. PubMed ID: 23992517
[TBL] [Abstract][Full Text] [Related]
2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
6. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
9. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
10. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP; Halperin JL
Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
[TBL] [Abstract][Full Text] [Related]
11. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
[TBL] [Abstract][Full Text] [Related]
12. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2013 Sep; 16(9):1163-8. PubMed ID: 23869941
[TBL] [Abstract][Full Text] [Related]
13. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation.
Aguilar MI; Kuo RS; Freeman WD
Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498
[TBL] [Abstract][Full Text] [Related]
14. Apixaban: a new factor Xa inhibitor for stroke prevention in patients with nonvalvular atrial fibrillation.
Lam S
Cardiol Rev; 2013; 21(4):207-12. PubMed ID: 23535530
[TBL] [Abstract][Full Text] [Related]
15. Apixaban for the prevention of stroke in atrial fibrillation.
Littrell R; Flaker G
Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
[TBL] [Abstract][Full Text] [Related]
17. A review of oral anticoagulants in patients with atrial fibrillation.
Greenspon AJ
Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
[TBL] [Abstract][Full Text] [Related]
18. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
[TBL] [Abstract][Full Text] [Related]
19. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
20. Role of emerging antithrombotic therapy in the prevention of cardioembolic complications in patients with atrial fibrillation.
Deedwania PC; Huang GW
Am J Cardiovasc Drugs; 2011 Aug; 11(4):265-75. PubMed ID: 21740079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
